Navigation Links
VIVUS Provides Regulatory Update on QNEXA
Date:9/15/2011

MOUNTAIN VIEW, Calif., Sept. 15, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that following a recent teleconference it has reached agreement with officials of the Endocrine and Metabolic Division of the Food and Drug Administration on a plan that allows for an early resubmission of the QNEXA New Drug Application for the treatment of obesity. The resubmission plan allows VIVUS to seek approval for an initial indication that includes obese men and women of non-child bearing potential.  Based on this agreement, VIVUS intends to resubmit the QNEXA NDA by the end of October 2011, prior to completion of the FORTRESS study. Top-line results from FORTRESS are expected in December 2011, with validation of FORTRESS expected in the third quarter of 2012. The FDA also stated that an Advisory Committee meeting for QNEXA will be held in the first quarter of 2012.

"Recent epidemiology study results, which show that topiramate is not a major teratogen, were an important consideration in our plan to resubmit the QNEXA NDA ahead of the FORTRESS results. The planned October resubmission will also allow for an early 2012 Advisory Committee meeting and a second quarter 2012 PDUFA date," commented Peter Y. Tam, president of VIVUS. "In this initial indication, we plan to include a contraindication for women of childbearing potential. We believe this is a sound approach that, if approved, will potentially allow early commercialization in a higher-risk population with a significant unmet medical need.  The FORTRESS study remains important in our plan to more precisely define the teratogenic potential of topiramate and may enable us to expand the indication to include obese women of child-bearing potential.  If the FORTRESS results are favorable, we expect to file for the full indication in late 2012."

According to the CDC, over 108 million adult Americans are
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
2. VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
3. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
4. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
5. VIVUS to Present at Three Upcoming Investor Conferences in March
6. VIVUS Provides Regulatory Update on QNEXA NDA
7. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
8. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
9. VIVUS to Present at Two Upcoming Investor Conferences
10. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
11. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Echo ... medical device company focused on skin permeation, continuous ... Scott W. Hollander has been appointed ... Hollander has more than 20 years of experience ... industries, and most recently served as Vice President, ...
(Date:12/24/2014)... DALLAS , December 24, 2014 /PRNewswire/ ... Research Report on Global Disposable Syringe Industry ... to its online business intelligence library. ... Global Disposable Syringe Industry is a professional ... Syringe market.  For overview analysis, the report ...
(Date:12/24/2014)... 23, 2014  Lockton Dunning Benefits, the ... announced the addition of Vice President Kim ... Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... experience to the position.  Most recently, she worked ... Diplomat Specialty Pharmacy, where she has held various ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5Kim Foerster Joins Lockton Companies 2
... Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, ... Capital Markets 6th Annual Healthcare Conference on November 17, 2009 ... New York City. Dr. Fernandes will provide an overview ... treatment of drug-resistant pathogens including MRSA. , About Cempra ...
... Nov. 13 Warner Chilcott plc (Nasdaq: WCRX ... its ordinary shares by certain selling shareholders. The ... DLJ Merchant Banking, J.P. Morgan Partners (advised by CCMP ... institutional investors and members of the Company,s senior management. ...
Cached Medicine Technology:Warner Chilcott Announces Secondary Equity Offering 2Warner Chilcott Announces Secondary Equity Offering 3Warner Chilcott Announces Secondary Equity Offering 4
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses and ... of black one-shoulder cocktail dresses . In addition, all ... at discounted prices, up to 70% off. , ... weeks only. You know, we have thousands of frequent callers ... new items can visit our website for more details. The ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business ... company announces big discounts on its bamboo mats ... BambooFlooringChina.com is the world’s leader in bamboo flooring. According ... Jan. 20, 2015. , The bamboo mats are made ... thread. All the bamboo strips for the mats are ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Very sick children with complex chronic illnesses can receive effective, ... "medical home," with easy access to a team of dedicated ... less likely to become seriously ill and need either hospitalization ... treatment at an enhanced medical home clinic at the University ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... a "fountain of youth" drug that can delay the effects ... new study suggests. Seniors received a significant boost to ... genetic signaling pathway linked to aging and immune function, researchers ... experimental medication, a version of the drug rapamycin, improved the ...
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... study published in the journal Acta Obstetricia et ... (body mass index, BMI) and weight gain in pregnancy ... since high birthweight may also predict adult overweight. ... Department of Pediatrics at Soerlandet Hospital and the University ...
... A large-scale analysis of patients whose myelodysplastic syndrome is ... all of them have a poor prognosis, researchers from ... at the 53rd Annual Meeting of the American Society ... earlier radiation, chemotherapy or both treatments are usually told ...
... apricot - telling these smells apart is no problem for ... smells has been uncovered by an interdisciplinary team of researchers ... light on the dynamics of the three-dimensional structure of the ... also found a characteristic pattern of hydrogen bonds between odorant ...
... San Diego, CA -- After the US Prostate Cancer Prevention ... prostate specific antigen (PSA), many debated which PSA level should ... Task Force (USPSTF) recently concluded, amid considerable controversy, that the ... 75 years old at all, because the risks outweigh the ...
... HealthDay Reporter , MONDAY, Dec. 12 (HealthDay News) -- ... frequently undergo an MRI beforehand. But a new study finds ... value for these patients. Researchers at Johns Hopkins University ... improve results for patients who are candidates for the injection, ...
... a new collaboration with the American College of Physicians ... to 100 practices free, one-year access to a new ... serve their patients. The tool, known as the Medical ... how IBC is working with area physicians and respected ...
Cached Medicine News:Health News:Prognostic model developed for MDS related to prior cancer therapy 2Health News:Prognostic model developed for MDS related to prior cancer therapy 3Health News:A good nose: RUB-Researchers decipher interaction of fragrances and olfactory receptors 2Health News:Biopsy referral after PSA screening stays consistent over time 2Health News:Study Questions Use of MRI Before Back-Pain Injections 2Health News:Study Questions Use of MRI Before Back-Pain Injections 3Health News:Independence Blue Cross teams with American College of Physicians to improve primary care 2
Reliable and Affordable. The Schuco 3000 Nebulizer by Allied has been designed to offer a compact style that provides worry-free affordable nebulizer therapy....
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
... Nebulizers deliver particulate humidity in the 3 ... secretion patients. For your convenience, Thera-Mist® nebulizers ... of sterile water., ,The P30000N, for ... 20-50% with a total flow range of ...
... Hand Held Nebulizer can be held at angles ... has a built in spill column, finger grooves ... medication setups and 7 feet of regular oxygen ... maintain small particle size and sustain optimum mist ...
Medicine Products: